A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
BRAF V600
chart review
dabrafenib
melanoma
real-world
trametinib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
10
03
2021
revised:
21
04
2021
accepted:
23
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable long-term efficacy in patients with
Identifiants
pubmed: 34070224
pii: cancers13102466
doi: 10.3390/cancers13102466
pmc: PMC8158680
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Novartis
ID : None
Références
Eur J Cancer. 2017 Sep;82:45-55
pubmed: 28648698
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
Lancet Oncol. 2017 Jul;18(7):863-873
pubmed: 28592387
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
J Clin Oncol. 2013 Sep 10;31(26):3205-11
pubmed: 23918947
BMC Cancer. 2018 Apr 27;18(1):490
pubmed: 29703161
Sci Rep. 2015 Apr 22;5:9800
pubmed: 25902419
Lancet Oncol. 2016 Dec;17(12):1743-1754
pubmed: 27864013
JAMA Oncol. 2018 Oct 1;4(10):1382-1388
pubmed: 30073321
Lancet Oncol. 2012 Nov;13(11):1087-95
pubmed: 23051966
Ann Oncol. 2015 Feb;26(2):415-21
pubmed: 25411413
J Neurooncol. 2017 Dec;135(3):507-512
pubmed: 28819707
Melanoma Res. 2020 Jun;30(3):261-267
pubmed: 31895752
Melanoma Res. 2019 Oct;29(5):527-532
pubmed: 31095039
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492